ONDANSETRON (GR38032F) PLUS DEXAMETHASONE - EFFECTIVE ANTIEMETIC PROPHYLAXIS FOR PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY

被引：49

作者：

SMITH, DB

NEWLANDS, ES

SPRUYT, OW

BEGENT, RHJ

RUSTIN, GJS

MELLOR, B

BAGSHAWE, KD

机构：

[1] Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross Hospital, London

来源：

BRITISH JOURNAL OF CANCER | 1990年 / 61卷 / 02期

关键词：

D O I：

10.1038/bjc.1990.62

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：323 / 324

页数：2

共 9 条

[1]

ARMITAGE P, 1987, STATISTICAL METHODS

[2] 5-HYDROXYTRYPTAMINE M-RECEPTOR ANTAGONISM TO PREVENT CISPLATIN-INDUCED EMESIS [J].

COSTALL, B ;

DOMENEY, AM ;

NAYLOR, RJ ;

TATTERSALL, FD .

NEUROPHARMACOLOGY, 1986, 25 (08) :959-961

[3] PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST [J].

CUNNINGHAM, D ;

POPLE, A ;

FORD, HT ;

HAWTHORN, J ;

GAZET, JC ;

CHALLONER, T ;

COOMBES, RC .

LANCET, 1987, 1 (8548) :1461-1463

[4]

CUNNINGHAM D, 1989, LANCET, V1, P1323

[5] DOSE-RANGING EVALUATION OF THE SEROTONIN ANTAGONIST GR-C507/75 (GR38032F) WHEN USED AS AN ANTIEMETIC IN PATIENTS RECEIVING ANTICANCER CHEMOTHERAPY [J].

KRIS, MG ;

GRALLA, RJ ;

CLARK, RA ;

TYSON, LB .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :659-662

[6]

KRIS MG, 1985, CANCER, V55, P527, DOI 10.1002/1097-0142(19850201)55:3<527::AID-CNCR2820550310>3.0.CO

[7]

2-2

[8] INHIBITION OF CISPLATIN-INDUCED VOMITING BY SELECTIVE 5-HYDROXYTRYPTAMINE M-RECEPTOR ANTAGONISM [J].

MINER, WD ;

SANGER, GJ .

BRITISH JOURNAL OF PHARMACOLOGY, 1986, 88 (03) :497-499

[9]

SMITH DB, 1990, IN PRESS CANCER CHEM

← 1 →